INVIVYD, INC. Lessee, Operating Lease, Liability, to be Paid, Year One
INVIVYD, INC. (IVVD) had Lessee, Operating Lease, Liability, to be Paid, Year One of $411.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2022-11-10
- 2022-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $411.00K.
- 2022-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $1.11M.
- 2022-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $411.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2022-09-30 | $411.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $1.11M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $411.00K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |